copi
number
variat
cnv
human
genom
convent
detect
use
highthroughput
scan
technolog
compar
genom
hybrid
highdens
singl
nucleotid
polymorph
snp
microarray
rel
lowthroughput
techniqu
quantit
polymeras
chain
reaction
pcr
approach
limit
resolut
best
distinguish
twofold
differ
copi
number
develop
new
technolog
studi
copi
number
use
platform
known
digit
array
nanofluid
biochip
capabl
accur
quantit
gene
interest
dna
sampl
evalu
digit
array
perform
use
model
system
show
technolog
exquisit
sensit
capabl
differenti
littl
differ
gene
copi
number
copi
target
gene
also
analyz
commerci
dna
sampl
copi
number
confirm
result
consist
obtain
independ
use
convent
techniqu
screen
experi
breast
cancer
normal
dna
sampl
gene
found
amplifi
breast
cancer
sampl
use
digit
array
enabl
accur
measur
gene
copi
number
signific
valu
cnv
studi
variat
human
genom
occur
multipl
level
singl
nucleotid
polymorph
snp
duplic
delet
contigu
block
dna
sequenc
copi
number
variat
cnv
import
polymorph
dna
segment
across
wide
rang
size
one
primari
sourc
variat
human
genom
recent
cnv
studi
extens
close
associ
larg
number
human
disord
understand
variat
import
understand
full
spectrum
human
genet
variat
also
assess
signific
variat
diseaseassoci
studi
first
human
cnv
map
construct
studi
normal
individu
total
cnv
region
whole
genom
cnv
found
human
genom
http
project
tcagcavari
recent
paper
demonstr
presenc
novel
insert
sequenc
across
genom
eight
unrel
individu
present
human
refer
genom
show
mani
differ
copi
number
howev
current
cnv
analysi
mainli
depend
upon
microarraybas
snp
compar
genom
hybrid
cgh
platform
dna
sequenc
therefor
subject
low
sensit
low
resolut
techniqu
high
throughput
lack
flexibl
analyz
individu
gene
sequenc
interest
exist
technolog
quantit
polymeras
chain
reaction
pcr
limit
inabl
reliabl
distinguish
less
twofold
differ
copi
number
particular
gene
dna
sampl
studi
demonstr
use
uniqu
integr
nanofluid
system
digit
array
studi
cnv
digit
array
abl
accur
quantit
dna
sampl
base
fact
singl
dna
molecul
randomli
distribut
reaction
chamber
pcr
amplifi
concentr
sequenc
dna
sampl
copiesml
calcul
use
number
posit
chamber
contain
least
one
copi
sequenc
order
ensur
appar
differ
gene
copi
number
differ
sampl
real
distort
differ
sampl
amount
use
express
rel
copi
number
rel
copi
number
gene
number
copi
gene
per
haploid
genom
easili
express
ratio
copi
number
target
gene
copi
number
singl
copi
refer
gene
two
copi
per
cell
dna
sampl
alway
per
haploid
genom
use
two
assay
two
gene
gene
interest
refer
gene
two
fluoresc
dye
digit
array
abl
simultan
quantit
gene
dna
sampl
ratio
number
molecul
two
gene
rel
copi
number
gene
interest
dna
sampl
singl
copi
gene
rel
copi
number
rel
copi
number
greater
indic
presenc
duplic
target
gene
number
smaller
impli
delet
gene
data
show
digit
array
abl
distinguish
less
twofold
differ
gene
copi
number
differenti
copi
gene
great
accuraci
provid
reliabl
robust
platform
studi
copi
number
variat
great
advantag
convent
techniqu
sequenc
synthet
construct
sequenc
primer
probe
use
amplifi
construct
shown
supplementari
taqman
assay
rnase
p
gene
vic
order
appli
biosystem
foster
citi
ca
feasibl
digit
pcr
previous
demonstr
perform
pcr
singl
dna
sampl
obtain
serial
dilut
process
target
molecul
dna
sampl
could
quantit
count
number
posit
reaction
util
principl
partit
instead
dilut
order
identifi
quantit
individu
dna
molecul
fluidigm
digit
array
novel
nanofluid
biochip
digit
pcr
reaction
perform
util
nanoscal
valv
pump
digit
array
deliv
mixtur
sampl
pcr
reagent
individu
panel
panel
contain
independ
chamber
nanofluid
platform
util
soft
lithographi
silicon
rubber
creat
nanoscal
valv
pump
use
serial
parallel
applic
digit
array
compos
pdm
silicon
rubber
integr
fluidic
circuit
integr
heat
spreader
ensur
rapid
heat
transfer
temperatur
uniform
within
array
sbsformat
carrier
input
pressur
accumul
act
interfac
user
pdm
chip
carrier
input
correspond
separ
sampl
input
chip
individu
sampl
minimum
volum
ml
deliv
preprogram
partit
chamber
chip
pressuredriven
blind
fill
pdm
control
line
prime
control
fluid
pressur
actuat
valv
reaction
chamber
valv
partit
individu
chamber
kept
close
pcr
experi
one
import
applic
digit
array
absolut
quantit
dna
molecul
mixtur
randomli
partit
chamber
panel
chip
thermocycl
fluidigm
biomark
system
posit
chamber
origin
contain
one
molecul
gener
fluoresc
signal
count
digit
pcr
analysi
softwar
sinc
volum
dilut
factor
dna
sampl
known
prior
load
digit
array
dna
concentr
accur
calcul
precis
test
depend
upon
sampl
random
like
biolog
experi
improv
multipl
test
panel
digit
array
routin
use
us
quantit
dna
sampl
unknown
concentr
especi
cdna
sampl
whose
concentr
sequenc
interest
hard
determin
otherwis
duplic
occur
multipl
copi
gene
might
close
link
chromosom
therefor
might
separ
even
digit
array
result
multipl
copi
might
behav
singl
molecul
total
number
copi
gene
would
underestim
two
copi
separ
larg
genom
distanc
might
separ
dna
molecul
fragment
purif
howev
case
would
suffici
see
tabl
sampl
genom
dna
data
specif
target
amplif
sta
good
solut
problem
sta
simpl
pcr
reaction
primer
refer
gene
gene
interest
typic
perform
limit
number
thermal
cycl
five
studi
copi
number
gene
proport
increas
use
process
multipl
copi
gene
interest
amplifi
separ
later
randomli
partit
chamber
digit
array
sinc
newli
gener
molecul
gene
reflect
origin
ratio
link
digit
chip
analysi
quantit
molecul
two
gene
measur
ratio
therefor
copi
number
gene
interest
accur
figur
import
amplif
effici
two
pair
primer
approxim
equal
order
introduc
bia
ratio
two
gene
copi
number
limit
number
sta
thermal
cycl
although
like
insignific
effect
result
sinc
util
five
cycl
preamplif
amplif
effici
pair
primer
easili
measur
use
realtim
pcr
sta
perform
geneamp
pcr
system
appli
biosystem
foster
citi
ca
ml
reaction
contain
taqman
preamp
master
mix
appli
biosystem
foster
citi
ca
nm
primer
rnase
p
target
gene
ng
dna
thermocycl
condit
min
hot
start
five
cycl
min
product
dilut
prior
copi
number
analysi
digit
array
base
initi
concentr
would
rnase
p
molecul
per
panel
copi
number
analysi
use
digit
array
biomark
system
panel
digit
array
contain
total
ml
nl
chamber
pcr
reaction
mix
howev
ml
reaction
mix
normal
prepar
panel
contain
taqman
gene
express
master
mix
appli
biosystem
foster
citi
ca
rnase
pvic
taqman
assay
taqman
assay
nm
primer
nm
probe
target
gene
sampl
load
reagent
fluidigm
south
san
francisco
ca
dna
copi
rnase
p
gene
reaction
mix
uniformli
partit
reaction
chamber
panel
digit
array
thermocycl
biomark
system
http
wwwfluidigmcomproductsbiomarkmainhtml
thermocycl
condit
includ
min
hot
start
follow
cycl
twostep
pcr
denatur
min
anneal
extens
molecul
two
gene
independ
amplifi
fam
vic
signal
chamber
record
end
pcr
cycl
reaction
complet
digit
pcr
analysi
softwar
fluidigm
south
san
francisco
ca
use
process
data
count
number
famposit
chamber
target
gene
vicposit
chamber
rnase
p
panel
chamber
panel
digit
array
singl
dna
molecul
randomli
partit
chamber
possibl
multipl
molecul
could
partit
chamber
result
could
molecul
panel
posit
chamber
true
number
molecul
per
chamber
estim
use
simpl
poisson
distribut
equat
describ
sindelka
et
al
develop
robust
comput
algorithm
analyz
cnv
data
obtain
digit
array
algorithm
integr
digit
pcr
analysi
softwar
detail
proofofprincipl
spikein
experi
perform
use
synthet
construct
explor
digit
array
feasibl
robust
platform
cnv
studi
oligonucleotid
ident
fragment
human
order
integr
dna
technolog
coralvil
ia
usa
rnase
p
singl
copi
gene
use
refer
studi
synthet
construct
human
genom
dna
coriel
cell
repositori
camden
nj
usa
quantit
use
assay
digit
array
differ
amount
synthet
construct
spike
genom
dna
mixtur
ratio
rnase
p
spikein
made
simul
dna
sampl
contain
two
seven
copi
gene
spikein
mixtur
analyz
digit
array
five
panel
use
mixtur
rnase
p
molecul
present
panel
ratio
p
sampl
calcul
plot
expect
ratio
figur
good
linear
relationship
observ
also
shown
figur
exampl
typic
digit
array
experi
cnv
gene
belong
cytochrom
system
respons
metabol
mani
commonli
prescrib
medic
gene
highli
polymorph
significantli
influenc
metabol
activ
enzym
code
debrisoquin
therapeut
efficaci
drug
therefor
pharmacogenet
polymorph
inform
gene
would
great
clinic
import
therapeut
decisionmak
allel
gene
identifi
http
wwwcypallel
alleleassoci
variat
activ
enzym
observ
individu
carri
allel
classifi
poor
intermedi
extens
ultrarapid
metabol
genotyp
patient
would
abl
identifi
risk
sever
toxic
respons
poor
metabol
need
standard
level
drug
ultra
rapid
metabol
shown
poor
metabol
ultra
rapid
metabol
caus
delet
duplic
entir
gene
larg
structur
chang
detect
use
convent
technolog
southern
blot
longrang
pcr
howev
believ
realtim
pcr
figur
quantit
copi
number
spikein
sampl
contain
two
seven
copi
molecul
per
two
haploid
genom
xaxi
show
expect
ratio
number
molecul
rnase
p
molecul
yaxi
show
observ
ratio
valu
calcul
use
five
panel
sampl
mix
error
bar
repres
standard
error
good
linear
correl
seen
coeffici
determin
r
current
promis
techniqu
abl
provid
inform
exact
copi
number
gene
routin
clinic
set
use
digit
array
measur
copi
number
three
dna
sampl
paragondx
morrisvil
nc
genotyp
dna
sampl
character
tabl
sampl
statreat
see
figur
materi
method
section
product
analyz
use
five
panel
digit
array
rel
copi
number
three
sampl
respect
highli
consist
assum
diploid
copi
number
base
upon
genotyp
also
studi
five
cell
line
dna
sampl
coriel
cell
repositori
camden
nj
first
measur
rel
copi
number
use
genom
dna
result
show
two
singl
copi
two
two
copi
gene
per
cell
tabl
one
sampl
rel
copi
number
equal
diploid
copi
number
statreat
five
sampl
ran
product
digit
array
rel
copi
number
sampl
remain
fifth
sampl
show
rel
copi
number
diploid
copi
number
appar
sampl
duplic
gene
one
two
chromosom
previous
demonstr
duplic
occur
two
copi
separ
kb
therefor
diploid
copi
number
obtain
genom
dna
use
like
result
dna
breakag
kb
genom
region
dna
molecul
separ
two
copi
confirm
ran
long
rang
pcr
see
duplic
observ
sampl
rel
copi
number
figur
also
known
receptor
tyrosin
kinas
gene
overexpress
invas
breast
cancer
result
loss
normal
cellular
growth
control
case
caus
amplif
gene
number
extra
copi
close
relat
protein
express
level
amplif
well
correl
aggress
phenotyp
character
reduc
respons
chemotherapi
high
recurr
rate
short
surviv
time
serv
signific
prognost
predictor
breast
cancer
patient
trastuzumab
herceptin
fdaapprov
monoclon
antibodi
protein
shown
dramat
increas
respons
rate
extend
surviv
breast
cancer
patient
amplif
given
trastuzumab
proven
efficaci
substanti
benefit
multipl
clinic
trial
detect
amplif
becom
critic
differ
methodolog
determin
statu
breast
cancer
immunohistochemistri
ihc
fluoresc
situ
hybrid
fish
two
fdaapprov
technolog
detect
amplif
former
detect
overexpress
receptor
cell
membran
latter
detect
copi
number
gene
rel
chromosom
centromer
ihc
less
expens
easi
perform
prone
high
rate
inaccuraci
due
variat
tissu
prepar
protein
stabil
antibodi
sensit
score
subject
hand
fish
accur
good
clinic
correl
expens
time
consum
labor
intens
requir
experienc
personnel
therefor
suggest
made
use
combin
ihc
fish
ihc
use
screen
procedur
follow
fish
confirm
necessari
use
digit
array
analyz
copi
number
breast
cancer
normal
breast
tissu
dna
sampl
biochain
hayward
ca
dna
sampl
asian
individu
except
one
normal
sampl
caucasian
breast
cancer
sampl
adenocarcinoma
fibroadenoma
invas
lobular
carcinoma
infiltr
ductal
carcinoma
invas
ductal
carcinoma
sampl
statreat
screen
purpos
product
analyz
use
two
panel
sampl
digit
array
result
shown
figur
fourteen
breast
cancer
sampl
diploid
copi
number
five
control
sampl
five
copi
absolut
number
copi
greater
per
cell
consid
amplif
fish
analysi
use
five
threshold
copi
number
shown
integ
due
heterogen
cancer
cell
ii
sampl
variat
two
panel
use
sampl
realtim
pcr
reaction
also
perform
sampl
twentyfour
replic
use
sampl
although
averag
copi
number
close
digit
array
data
larg
fluctuat
sd
observ
reaction
sampl
studi
gene
exampl
show
realtim
pcr
alway
produc
accur
result
data
shown
genomewid
analys
shown
exist
larg
number
cnv
entir
human
genom
larg
interindividu
divers
mani
cnv
coloc
gene
involv
varieti
diseas
diseas
suscept
believ
play
role
pathogenesi
first
mendelian
disord
associ
amplif
kb
dna
fragment
report
recent
appear
result
genom
dna
sta
product
shown
ratio
gene
rnase
p
gene
close
multipl
genom
ratio
sampl
correspond
diploid
copi
number
reflect
partial
separ
duplic
allel
genom
dna
ratio
diploid
copi
number
obtain
sampl
subject
sta
prior
digit
pcr
analysi
question
time
genet
condit
relat
cnv
identifi
two
standard
genomewid
scan
method
cnv
detect
arraybas
cgh
highdens
snp
genotyp
array
employ
construct
first
human
cnv
map
microarray
techniqu
abl
gener
wholegenom
cnv
data
import
cnv
discoveri
resolut
also
improv
develop
new
probe
howev
sinc
base
hybrid
detect
copi
number
chang
larg
depend
signaltonois
ratio
sensit
reagent
manufactur
variabl
therefor
fals
posit
fals
neg
result
sometim
inevit
addit
lack
standard
refer
genom
studi
use
technolog
complic
interpret
result
mani
occas
geneor
locusspecif
whole
genom
copi
number
inform
requir
especi
true
case
describ
therapeut
decis
need
made
base
upon
copi
number
gene
addit
convent
method
southern
blot
longrang
pcr
fish
possibl
use
quantit
pcr
cnv
studi
two
gene
previous
explor
quantit
pcr
simpl
easi
perform
howev
sinc
copi
number
target
gene
deriv
ct
differ
target
gene
refer
gene
result
sensit
effici
amplif
reaction
even
one
compens
amplif
effici
consid
difficult
obtain
discrimin
power
better
twofold
digit
array
abil
absolut
quantit
type
dna
sampl
multiplex
pcr
reaction
two
assay
quantit
two
genessequ
singl
sampl
becom
possibl
effect
elimin
pipet
variat
inher
occur
quantit
experi
accuraci
result
subject
random
distribut
molecul
like
biolog
experi
improv
use
multipl
replic
sampl
sta
effici
separ
link
copi
gene
chromosom
duplic
occur
method
restrict
digest
also
valid
data
shown
perform
three
experi
test
feasibl
digit
array
cnv
studi
first
measur
copi
number
gene
seri
mixtur
made
human
genom
dna
synthet
construct
observ
good
correl
result
expect
outcom
studi
copi
number
dna
sampl
either
genotyp
elsewher
character
us
use
convent
techniqu
result
also
consist
lastli
screen
breast
cancer
sampl
amplif
gene
although
clinic
data
patholog
classif
sampl
lack
sampl
increas
number
gene
close
amplif
frequenc
report
literatur
conclus
studi
show
digit
array
provid
new
robust
technolog
studi
geneand
sequencespecif
cnv
abl
detect
gene
copi
number
great
accuraci
digit
array
provid
much
greater
discrimin
power
quantit
pcr
cnv
studi
digit
array
easi
perform
fast
data
obtain
easi
interpret
furthermor
platform
flexibl
tailor
genesequ
also
serv
independ
measur
verifi
result
wholegenom
scan
use
array
technolog
digit
array
excel
cnv
platform
basic
research
clinic
investig
supplementari
data
avail
nar
onlin
fund
open
access
charg
fluidigm
corpor
conflict
interest
statement
author
declar
compet
financi
interest
employe
fluidigm
corpor
